• Je něco špatně v tomto záznamu ?

Analysis of extracorporeal photopheresis within the frame of the WAA register

M. Blaha, Z. Gasova, G. Berlin, J. Audzijoniene, A. Griskevicius, J. Dykes, Z. Bhuiyanova, M. Lanska, T. Eich, H. Vrielink, V. Witt, GC. Seval, O. Ilhan, B. Stegmayr

. 2021 ; 60 (5) : 103172. [pub] 20210527

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22012181

The aim of the study was to investigate safety and if extracorporeal photopheresis (ECP) may change health criteria (HC) and quality of life (QoL).MATERIAL AND METHOD: 560 patients (33 % women) were treated with ECP for a total of 13,871 procedures during a 17-years period. Mean age was 48 years (±18, range 3-81 years). Self-estimation of QoL was graded: 0 (suicidal) up to 10 (best ever) and HC: 0 (Bed ridden, ICU condition) up to 10 (athletic). Adverse events were analyzed. ANOVA and paired comparisons were performed. RESULTS: Patients were treated due to graft versus host disease (GVHD, n = 317), skin lymphoma (n = 70), solid organ transplants (n = 47), skin diseases (n = 20) and other diseases (n = 106). Adverse events (AEs) were registered in 5.4 % of the first treatments and in 1.2 % of the subsequent procedures. Severe AEs were present in 0.04 % of all procedures. No patient died due to the procedure. Tingling and stitching were the most common AE. For those with GVHD an improvement was noticed within approximately 10 procedures of ECP in the severity stage, QoL (from a mean of 6.1 to 6.8, p < 0.002) and the HC (6.1 -> 6.4, p < 0.014) and improved further with added procedures. CONCLUSION: Photopheresis is an established therapy with few side effects. The present study of soft variables indicate that GVHD shows benefits upon ECP within approximately 10 procedures in regard to the severity of mainly skin GVHD, and lower baseline levels of HC and QoL.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22012181
003      
CZ-PrNML
005      
20220506130433.0
007      
ta
008      
220425s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.transci.2021.103172 $2 doi
035    __
$a (PubMed)34059472
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Blaha, M $u Faculty Nemocnice Hradec Kralove, University Hospital Hradec Kralove, Hradec Králové, Czech Republic
245    10
$a Analysis of extracorporeal photopheresis within the frame of the WAA register / $c M. Blaha, Z. Gasova, G. Berlin, J. Audzijoniene, A. Griskevicius, J. Dykes, Z. Bhuiyanova, M. Lanska, T. Eich, H. Vrielink, V. Witt, GC. Seval, O. Ilhan, B. Stegmayr
520    9_
$a The aim of the study was to investigate safety and if extracorporeal photopheresis (ECP) may change health criteria (HC) and quality of life (QoL).MATERIAL AND METHOD: 560 patients (33 % women) were treated with ECP for a total of 13,871 procedures during a 17-years period. Mean age was 48 years (±18, range 3-81 years). Self-estimation of QoL was graded: 0 (suicidal) up to 10 (best ever) and HC: 0 (Bed ridden, ICU condition) up to 10 (athletic). Adverse events were analyzed. ANOVA and paired comparisons were performed. RESULTS: Patients were treated due to graft versus host disease (GVHD, n = 317), skin lymphoma (n = 70), solid organ transplants (n = 47), skin diseases (n = 20) and other diseases (n = 106). Adverse events (AEs) were registered in 5.4 % of the first treatments and in 1.2 % of the subsequent procedures. Severe AEs were present in 0.04 % of all procedures. No patient died due to the procedure. Tingling and stitching were the most common AE. For those with GVHD an improvement was noticed within approximately 10 procedures of ECP in the severity stage, QoL (from a mean of 6.1 to 6.8, p < 0.002) and the HC (6.1 -> 6.4, p < 0.014) and improved further with added procedures. CONCLUSION: Photopheresis is an established therapy with few side effects. The present study of soft variables indicate that GVHD shows benefits upon ECP within approximately 10 procedures in regard to the severity of mainly skin GVHD, and lower baseline levels of HC and QoL.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a dítě $7 D002648
650    _2
$a předškolní dítě $7 D002675
650    _2
$a chronická nemoc $7 D002908
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a nemoc štěpu proti hostiteli $x psychologie $x terapie $7 D006086
650    _2
$a hemodynamika $7 D006439
650    _2
$a lidé $7 D006801
650    _2
$a lymfom $x psychologie $x terapie $7 D008223
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a fotoferéza $x metody $7 D017893
650    _2
$a kvalita života $7 D011788
650    _2
$a registrace $7 D012042
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a nádory kůže $x psychologie $x terapie $7 D012878
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
700    1_
$a Gasova, Z $u Institute of Hematology and Blood Transfusion, UHKT, Prague, Czech Republic
700    1_
$a Berlin, G $u Dept Clinical Immunology and Transfusion Medicine, and Dpt Biomedical Clinical Science, Linköping University, Linköping, Sweden
700    1_
$a Audzijoniene, J $u Hematology, onkology and Transfusion Centre, University Hospital, Vilnius, Lithuania
700    1_
$a Griskevicius, A $u Hematology, onkology and Transfusion Centre, University Hospital, Vilnius, Lithuania
700    1_
$a Dykes, J $u Dept Hematology and Transfusion Medicine, University Lund, Lund, Sweden
700    1_
$a Bhuiyanova, Z $u Institute of Hematology and Blood Transfusion, UHKT, Prague, Czech Republic
700    1_
$a Lanska, M $u Faculty Nemocnice Hradec Kralove, University Hospital Hradec Kralove, Hradec Králové, Czech Republic
700    1_
$a Eich, T $u Dept Clinical Immunology and Transfusion Medicine, Uppsala Akademiska University Hospital, Uppsala, Sweden
700    1_
$a Vrielink, H $u Sanquin Blood Supply, the Netherlands
700    1_
$a Witt, V $u Apheresis Centres, St. Anna Kinderspital/MUW, Vienna, Austria
700    1_
$a Seval, G C $u Hematology, Ankara University School of Medicine, Ankara, Turkey
700    1_
$a Ilhan, O $u Hematology, Ankara University School of Medicine, Ankara, Turkey
700    1_
$a Stegmayr, B $u Dept Public Health and Clinical Medicine, Umea University, Umea, Sweden. Electronic address: bernd.stegmay@umu.se
773    0_
$w MED00008583 $t Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis $x 1473-0502 $g Roč. 60, č. 5 (2021), s. 103172
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34059472 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220425 $b ABA008
991    __
$a 20220506130425 $b ABA008
999    __
$a ok $b bmc $g 1789677 $s 1163382
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 60 $c 5 $d 103172 $e 20210527 $i 1473-0502 $m Transfusion and apheresis science $n Transfus Apher Sci $x MED00008583
LZP    __
$a Pubmed-20220425

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace